Mankind Pharma Limited has informed the Exchange about Transcript
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma reported Q4 FY26 revenue of INR 3,443 crore (+11.8% YoY) with adjusted EBITDA margin of 27.1%, up 400 bps from 23.1% in Q4 FY25. For full year FY26, revenue grew 17% to INR 14,278 crore with EBITDA margin of 25.4% (within guidance). PAT for Q4 surged 30.4% to INR 559 crore. Domestic business grew 13.4% in Q4 with organic growth of 10.1% (highest since BSV acquisition). Chronic therapy contribution increased to ~40% of revenue. The company launched its GLP-1 pen about a month ago, taking a cautious approach amid market competition. Net debt stands at INR 3,932 crore with net debt/EBITDA at 1.1x, on track for full repayment by FY28. The company approved INR 500 crore investment in its subsidiary Mankind Medicare for a new biotech facility in Vadodara.
Management provided optimistic FY27 guidance expecting better revenue growth and EBITDA margin in the range of 25.5-26.5%. The strong Q4 performance and BSV integration progress suggest operational challenges are largely behind, supporting a positive outlook for shareholders.